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 Acute Hemodynamic Eff ects of Riociguat in Patients 
With Pulmonary Hypertension Associated With 
Diastolic Heart Failure (DILATE-1) 
 A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study 
 Diana  Bonderman ,  MD ;  Ingrid  Pretsch ,  MD ;  Regina  Steringer-Mascherbauer ,  MD ;  Pavel  Jansa ,  MD ; 
 Stephan  Rosenkranz ,  MD ;  Caroline  Tufaro ,  MS ;  Andja  Bojic ,  MD ;  Carolyn S. P.  Lam ,  MD ;  Reiner  Frey ,  MD ; 
 Michael  Ochan Kilama ,  MD ;  Sigrun  Unger ,  MSc ;  Lothar  Roessig ,  MD ; and  Irene M.  Lang ,  MD 
 BACKGROUND:  Defi cient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophos-
phate signaling results from endothelial dysfunction and may underlie impaired cardiac relax-
ation in patients with heart failure with preserved left  ventricular ejection fraction (HFpEF) 
and pulmonary hypertension (PH). Th e acute hemodynamic eff ects of riociguat, a novel sol-
uble guanylate cyclase stimulator, were characterized in patients with PH and HFpEF. 
 METHODS:  Clinically stable patients receiving standard HF therapy with a left  ventricular ejec-
tion fraction  . 50%, mean pulmonary artery pressure (mPAP)   25 mm Hg, and pulmonary 
arterial wedge pressure (PAWP)  . 15 mm Hg at rest were randomized to single oral doses of 
placebo or riociguat (0.5, 1, or 2 mg). Th e primary effi  cacy variable was the peak decrease in 
mPAP from baseline up to 6 h. Secondary outcomes included hemodynamic and echocardio-
graphic parameters, safety, and pharmacokinetics. 
 RESULTS:  Th ere was no signifi cant change in peak decrease in mPAP with riociguat 2 mg 
(n  5 10) vs placebo (n  5 11,  P  5 .6). However, riociguat 2 mg signifi cantly increased stroke 
volume ( 1 9 mL [95% CI, 0.4-17];  P  5 .04) and decreased systolic BP ( 2 12 mm Hg [95% CI, 
 2 22 to  2 1];  P  5 .03) and right ventricular end-diastolic area ( 2 5.6 cm 2 [95% CI,  2 11 to  2 0.3]; 
 P  5 .04), without signifi cantly changing heart rate, PAWP, transpulmonary pressure gradient, 
or pulmonary vascular resistance. Riociguat was well tolerated. 
 CONCLUSIONS:  In patients with HFpEF and PH, riociguat was well tolerated, had no signifi cant 
eff ect on mPAP, and improved exploratory hemodynamic and echocardiographic parameters. 
 TRIAL REGISTRY:  ClinicalTrials.gov; No.: NCT01172756; URL: www.clinicaltrials.gov 
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 Manuscript received January 13, 2014; revision accepted May 15, 2014; 
originally published Online First July 3, 2014. 
 ABBREVIATIONS:  AE  5 adverse event; AF  5 atrial fi brillation; cGMP  5 
cyclic guanosine monophosphate; CO  5 cardiac output; DILATE  5 
Acute Hemodynamic Eff ects of Riociguat in Patients With Pulmonary 
Hypertension Associated With Diastolic Heart Failure; DPG  5 diastolic 
pressure gradient; HF  5 heart failure; HFpEF  5 heart failure with pre-
served left  ventricular ejection fraction; HR  5 heart rate; LA  5 left  atrial; 
LEPHT  5 Left  Ventricular Systolic Dysfunction Associated With Pulmo-
nary Hypertension Riociguat Trial; LV  5 left  ventricular; MAP  5 mean 
arterial pressure; mPAP  5 mean pulmonary artery pressure; MVO 2  5 
myocardial oxygen consumption; NO  5 nitric oxide; NO-sGC-cGMP  5 
nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate; 
O 2  5 oxygen; PAWP  5 pulmonary arterial wedge pressure; PH  5 pul-
monary hypertension; PVR  5 pulmonary vascular resistance; RVED  5 
right ventricular end-diastolic; sGC  5 soluble guanylate cyclase; 
SV  5 stroke volume; SVR  5 systemic vascular resistance; TPG  5 trans-
pulmonary pressure gradient 
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Public Hospital Elisabethinen, Linz, Austria; the Clinical Department 
of Cardiology and Angiology of the First Faculty of Medicine and 
General Teaching Hospital (Dr Jansa), Prague, Czech Republic; the 
Approximately 30% to 50% of patients with heart fail-
ure (HF) have a preserved left ventricular ejection frac-
tion (HFpEF), a condition associated with dismal
prognosisI and for which there are still no proven ther-
apies to improve outcomes.' Several pathophysiologic
mechanisms have been demonstrated in HFpEF, includ-
ing left ventricular (LV) diastolic dysfunction,' arterial
stiffening, and abnormalities of LV-arterial coupling.v
which may compromise LVenergetic efficiency. With
longstanding pulmonary venous congestion, the majority
of patients with HFpEF develop increased pulmonary
arterial pressures and pulmonary hypertension (PH).
PH has been shown to be a major determinant of mor-
tality in this population and represents a potential novel
therapeutic target in HFpEP,7
HF- and PH-related diseases are characterized by
endothelial dysfunctton.s-» Preclinical and small clin-
ical studies suggest that deficient nitric oxide-soluble
guanylate cyclase-cyclic guanosine monophosphate
(NO-sGC-cGMP) signaling is involved in impaired car-
diac relaxation/distensibility," Furthermore, low cyclic
guanosine monophosphate (cGMP) levels in myocardial
tissue may underlie abnormal cardiomyocyte functton.»
Thus, targeting the NO-sGC-cGMP signaling pathway
Materials and Methods
Study Design
DILATE-l (clinicaltrials.gov: NCTOll72756) was a double-blind, ran-
domized, placebo-controlled, parallel-group phase 2a study conducted
in five centers across Austria, the Czech Republic, and Germany. Patients
received oral placebo or riociguat 0.5 mg, 1 mg, or 2 mg in three subse-
quent ascending dose cohorts.
The following local ethics committees approved the research protocol
(EudraCT number: 2010-018436-41): Ethics Committee of the Medical
University of Vienna and the General Hospital ofVienna-AKH, Ethics
Clinic III for Internal Medicine (Dr Rosenkranz), Heart Center at the
University Hospital of Cologne, Cologne, Germany; the National Univer-
sity Health System (Dr Lam), Singapore; Bayer HealthCare Pharmaceu-
ticals (Drs Frey and Roessig and Ms Unger), Wuppertal, Germany; and
Bayer HealthCare Pharmaceuticals (Dr Ochan Kilama), Milan, Italy.
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may be a promising approach for the treatment of
HFpEF with PH.
Riociguat is a novel soluble guanylate cyclase (sGC)
stimulator' swith a dual mode of action, sensitizing sGC
to endogenous nitric oxide (NO) and directly stimu-
lating sGC independent ofNO.16 Riociguat induces
vasodilation and has antifibrotic, antiproliferative, and
antiinflammatory effects.IS,ISIn clinical studies, riociguat
has proven efficacyin pulmonary arterial hypertension
and chronic thromboembolic PH.19,20 In a randomized,
placebo-controlled phase 2b study in patients with HF
and PH due to systolic LVdysfunction (Left Ventricular
SystolicDysfunction Associated With Pulmonary Hyper-
tension Riociguat Trial [LEPHT]), riociguat was well
tolerated and improved cardiac index, pulmonary (PVR)
and systemic vascular resistance (SVR), as well as
quality of life, without significantly changing mean
pulmonary artery pressure (mPAP, primary end point)
or systolic Bp'21 In the current study (Acute Hemody-
namic Effects of Riociguat in Patients With Pulmonary
Hypertension Associated With Diastolic Heart Failure
[DILATE-I]), we aimed to characterize the hemodynamic
effects, safety, and pharmacokinetics of single oral doses
of riociguat in patients with HFpEF and PH.
Committee of the A.o. Hospital Elisabethinen, Ethics Committee for
the State of Salzburg, Ethics Committee of the University of Prague, and
Ethics Committee of the Medical Faculty of the University of Cologne.
Written informed consent was obtained from patients in accordance
with the Declaration of Helsinki.
Patient Population
Eligible patients were those aged:2e: 18 years with symptomatic HFpEF
and PH despite optimized therapy with a stable dose of standard
medication for the control of symptoms and risk factors for > 30 days
(:2e: 7 days for diuretic therapy). Detailed inclusion and exclusion criteria
are provided in e-Appendix 1.
Study Procedures
Right -sided heart catheterization was performed by insertion of a
balloon-tipped pulmonary artery thermodilution catheter via the right
internal jugular vein. Hemodynamic and echocardiographic parame-
ters were recorded at regular intervals up to 6 h after intake of study
drug. Blood samples for pharmacokinetics and exploratory biomarkers
were taken at regular intervals up to 24 h after intake of study drug.
Safety was assessed via unblinded data review by an independent data-
monitoring committee. Additional safety follow-ups occurred on days 14
and 30 after study drug administration.
Outcome Measures
The primary efficacy variable was the peak decrease from baseline in
mPAP, defined as the largest mPAP change from baseline up to 6 h after
study drug administration. Secondary variables included additional
hemodynamic and echocardiographic parameters, biomarker levels,
safety variables, and pharmacokinetics. For the secondary hemody-
namic and echocardiographic variables, the mean change from baseline
of all evaluations up to 6 h after study drug administration was cal-
culated. Safety was assessed by adverse events (AEs), vital signs, and
laboratory evaluations, as defined in e-Appendix 1.
1275
 1276  Original Research  [   1 4 6  #  5   C H E S T   N OV E M B E R   2 0 1 4   ] 
 Post hoc exploratory estimation of myocardial oxygen consumption 
(MVO 2 ) was carried out as defined in  e-Appendix 1 . All patients 
who completed hemodynamic assessment were eligible for pharma-
cokinetic analysis. Details of pharmacokinetic analysis are provided in 
 e-Appendix 1 . 
 Statistical Analysis 
 Statistical analyses were performed using Statistical Analysis System 
(SAS Institute Inc). Th e analysis of effi  cacy was performed in patients 
valid for per-protocol analysis. Th e primary variable was assessed using 
a two-group, two-sided  t test on the riociguat 2 mg group vs placebo at 
the .05 signifi cance level. 
 Exploratory analysis of the secondary effi  cacy and post hoc variables 
was via analysis of variance, with treatment and time aft er study drug 
administration as main eff ects and a treatment by time interaction. 
Th is was followed by sequential pairwise comparisons between the 
three riociguat doses and placebo based on least squares means. AEs 
were analyzed descriptively in the safety population (all randomized 
patients). All values displayed are means   SD unless stated otherwise. 
 Results 
 Demographic Data 
 Of the 46 patients screened, 39 were eligible for study 
participation and 36 completed all study examinations 
( Fig 1 ). Demographic and clinical characteristics are 
shown in  Table 1 . A high proportion of patients had 
comorbidities typical of HFpEF, including history of atrial 
fi brillation (AF) (69%), AF at baseline (44%), diabetes 
mellitus (44%), coronary artery disease (17%), and 
COPD (19%). Th e majority of patients received antihy-
pertensive and diuretic therapy during the study: 47% 
angiotensin-converting enzyme inhibitors, 36% angio-
tensin II receptor antagonists, 44% aldosterone antago-
nists, 81%  b -blockers, and 67% loop diuretics ( Table 2 ). 
 Hemodynamics 
 Hemodynamic parameters at baseline are provided in 
 Table 3 . Th ere was no signifi cant change in the primary 
variable—peak decrease in mPAP from baseline up to 6 h 
aft er study drug administration—in the riociguat 2 mg 
group vs placebo group ( P  5 .6) ( Figs 2, 3 ,  e-Table 1 ). 
However, stroke volume (SV) ( P  5 .04) and cardiac index 
( P  5 .001) were signifi cantly increased in the riociguat 2 mg 
group compared with the placebo group, in the absence 
of increases in pulmonary arterial wedge pressure (PAWP) 
( P  5 .9) and signifi cant changes in heart rate (HR) ( P  5 .5) 
( Fig 3 ,  Table 3 ). In parallel, SVR ( P  , .05), mean arterial 
pressure (MAP) ( P  5 .04), and systolic BP ( P  5 .03) signif-
icantly decreased in the riociguat 2 mg group vs placebo 
( Fig 3 ,  Table 3 ) without signifi cant changes in transpul-
monary pressure gradient (TPG) and PVR. Within-group 
changes in secondary hemodynamic parameters are pro-
vided in  e-Table 2 . All hemodynamic changes occurred 
without an increase in the estimated MVO 2 (mean 
decrease:  2 0.1 mL oxygen [O 2 ]/min/100 g) ( e-Table 3 ). 22 
 Although the prospective randomized design minimized 
baseline imbalances, some diff erences were evident 
owing to the small sample size. Following adjustment 
for baseline diff erences between groups, changes in SV, 
SV index, SVR, cardiac output (CO), cardiac index, dia-
stolic BP, and MAP remained signifi cantly diff erent 
from placebo in the riociguat 2 mg group ( e-Table 4 ), 
whereas change in systolic BP did not signifi cantly diff er 
from the placebo group in this analysis. 
  
 Figure 1 – Patient disposition .  a n  5 1 
invalid for the PP population 
because of noncompliance with the 
protocol (laboratory parameters/
ECG assessed before informed con-
sent provided). All patients who 
completed the hemodynamic assess-
ments underwent a valid pharmaco-
kinetic analysis. One patient in the 
placebo group withdrew because of 
an AE of pain in the left  shoulder. 
AE  5 adverse event; PP  5 per 
protocol. 
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 TABLE 2 ]  Concomitant Cardiovascular Therapies Administered During the Study 
Drug Placebo (n  5 11)
Riociguat
Total (N  5 36)0.5 mg (n  5 8) 1 mg (n  5 7) 2 mg (n  5 10)
Angiotensin-converting enzyme 
inhibitors
3 (27) 2 (25) 6 (86) 6 (60) 17 (47)
Angiotensin II receptor antagonists 5 (45) 5 (63) 1 (14) 2 (20) 13 (36)
Aldosterone antagonists 7 (64) 2 (25) 2 (29) 5 (50) 16 (44)
 b -Blocking agents a 10 (91) 5 (63) 6 (86) 8 (80) 29 (81)
Calcium channel blockers 6 (55) 3 (38) 2 (29) 5 (50) 16 (44)
Amiodarone 0 1 (13) 0 3 (30) 4 (11)
Loop or high-ceiling diuretics 7 (64) 3 (38) 6 (86) 8 (80) 24 (67)
Thiazides or low-ceiling diuretics 2 (18) 3 (38) 3 (43) 5 (50) 13 (36)
Digitalis glycosides 3 (27) 3 (38) 2 (29) 0 8 (22)
Oral anticoagulants 7 (64) 6 (75) 5 (71) 5 (50) 23 (64)
 Data presented are No. (%) of patients in the per-protocol population. 
 a Includes one patient receiving carvedilol in the placebo group. 
 Echocardiography 
 At baseline, mean LV ejection fraction was 62.1%   6.9%, 
and LV end-diastolic volume index was 47.1   15.4 mL/m 2 . 
Left  atrial (LA) area was mildly enlarged (25.4   6.1 cm 2 ; 
range, 11.1-42.3 cm 2 ) at baseline; eight of 11 patients in 
the placebo group and nine of 10 in the riociguat 2 mg 
group had enlarged left  atria ( . 20 cm 2 ). 23 Compared 
with placebo, there was a signifi cant decrease in right 
ventricular end-diastolic (RVED) area ( 2 5.6 cm 2 
[95% CI,  2 10.9 to  2 0.3];  P  5 .04) from 23.8   11.5 cm 2 
at baseline (97.5 percentile of normal for men  . 24.7 cm 2 
and women 20.7 cm 2 ) 24 with riociguat 2 mg and a 
decrease in LA area ( 2 4.0 cm 2 [95% CI,  2 8.1 to 0.1]; 
 P  5 .06) ( e-Table 5 ). 
 Exploratory Biomarkers and Pharmacokinetics 
 Plasma N-terminal prohormone of brain natriuretic 
peptide, asymmetric dimethylarginine, ST2, and galectin-3 
revealed no diff erences in changes from baseline upon 
administration of riociguat compared with placebo 
( e-Table 6 ). Following single-dose administration of 
riociguat, plasma concentrations dose-dependently 
increased across the three active treatment groups 
( e-Fig 1 ). Peak plasma concentrations of riociguat were 
reached aft er a median of 1.9 to 2.5 h, and half-life was 
13.1 to 14.3 h ( e-Table 7 ). 
 Safety and Tolerability 
 Details of AEs during the study are provided in  Table 4 ; 
the majority of AEs were of mild or moderate intensity. 
Drug-related serious AEs were reported by two placebo 
group patients (15%) (two cases of decreased CO) and 
three patients (30%) taking riociguat 2 mg (one case of 
decreased CO and three cases of decreased MAP). 
 Regarding AEs of special interest, a fall in invasively 
measured systemic systolic arterial BP  , 80 mm Hg or 
in invasively measured MAP  , 60 mm Hg was reported 
by one patient (8%) taking placebo, one patient (13%) 
taking riociguat 1 mg, and three patients (30%) taking 
riociguat 2 mg. Two patients (15%) taking placebo and 
one patient (10%) taking riociguat 2 mg experienced a 
decrease in CO   20% of baseline. One patient (13%) 
taking riociguat 0.5 mg developed pulmonary edema, 
which was considered unrelated to study drug by the 
investigator. One patient (10%) in the riociguat 2 mg 
group experienced syncope 6 days aft er study drug; the 
AE was reported during the 30-day follow-up period 
and was associated with additional intake of sildenafi l. 
In the safety population, changes from baseline in arte-
rial O 2 saturation between 30 min and 6 h aft er adminis-
tration of riociguat were  2 0.2 to  1 0.7% in the placebo 
group,  2 0.2 to  2 1.7% in the riociguat 0.5 mg group, 
 2 0.4 to  1 0.8% in the 1 mg group, and  2 1.0 to  2 2.1% 
in the 2 mg group. 
 Th ere was one death (13%) in the riociguat 1 mg group. 
Th e patient died because of pulmonary hemorrhage, 
which was a complication of the protocol-required 
right-sided heart catheterization. 
 Th ere were no clinically relevant changes in vital signs, 
ECG, or any laboratory variables. A single patient (10%) 
in the riociguat 2 mg group with a history of paroxysmal 
AF had AF 24 h aft er drug intake. 
 journal.publications.chestnet.org  1279 
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 Figure 2 – Peak decrease in mPAP from baseline up to 6 h aft er adminis-
tration of study drug in the riociguat 2 mg group vs placebo group (pri-
mary end point). Th e diff erence between treatment groups was analyzed 
by a two-group, two-sided  t test. Th e treatment diff erence (95% CI) and 
 P value are also shown. mPAP  5 mean pulmonary artery pressure. 
 Discussion 
 Th e acute hemodynamic and echocardiographic eff ects 
of single doses of riociguat were investigated in patients 
with HFpEF and PH. Despite no signifi cant change in the 
primary end point—peak decrease in mPAP—favorable 
hemodynamic eff ects were observed in the riociguat 
2 mg group compared with placebo. Riociguat signifi -
cantly increased SV and cardiac index, and signifi cantly 
decreased systolic BP, SVR, and RVED area, without 
changing HR, PAWP, TPG, or PVR. Riociguat was well 
tolerated in combination with stable HF therapy. 
 Riociguat did not have the hypothesized eff ect—reduction 
in mPAP—in the current study in patients with HFpEF 
and PH, which was representative of an elderly, pre-
dominantly female HFpEF population with elevated 
PAWP and common comorbidities. As pulmonary 
selective vasodilators have been reported to worsen left -
sided heart fi lling pressures and induce pulmonary 
edema in patients with PH due to HFpEF, 25,26 the signifi -
cant increase in fl ow without an increase in PAWP 
might be refl ective of the systemic eff ects of riociguat. 
Although the contribution of aft erload-independent 
direct myocardial eff ects to this hemodynamic response 
was not addressed in the current study, the potential of 
direct sGC stimulators in HFpEF might go beyond 
hemodynamic eff ects and additionally, or even predom-
inantly, rely on nonhemodynamic eff ects of sGC-derived 
cGMP signaling in a variety of tissues, including cardiac 
myocytes. 27 
 Th e increase in SV was accompanied by a reduction 
in the size of the right ventricle. Experimental evidence 
suggests an essential role for sGC activity in load-
independent myocardial relaxation. 28 An alternative or 
additional explanation could be a decrease in mitral 
regurgitant volume as a consequence of reduced LV 
aft erload. A positive inotropic eff ect of riociguat is less 
likely, given the unaltered ventricular fi lling pressures. 
Furthermore, preclinical data suggest that sGC stimula-
tion does not increase cyclic adenosine monophosphate 
production despite signifi cant cGMP increases and may 
blunt the inotropic response to adrenergic 
stimulation. 29,30 
 Previous attempts to target the NO-sGC-cGMP pathway 
in HFpEF have shown confl icting results. Despite being 
  
 Figure 3 – Mean change (  SD) 
from baseline in selected hemody-
namic parameters in the 6 h 
following administration of study 
drug. A, Cardiac index. B, PAWP. C, 
SVR. D, MAP. MAP  5 mean arterial 
pressure; PAWP  5 pulmonary arte-
rial wedge pressure; SVR  5 systemic 
vascular resistance. 
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widely used as adjunctive therapies in HF, NO donors 
and organic nitrates are limited by the development of 
tolerance, oxidative stress, augmentation of endothelial 
dysfunction, and venoselectivity. 31 Th e hemodynamic 
response presented here is in agreement with the increase 
in cardiac index with 16 weeks’ riociguat in the LEPHT. 21 
By contrast, patients with HFpEF were fourfold more 
likely than those with HF with reduced ejection fraction to 
experience a reduction in SV with acute IV nitroprusside, 
suggesting greater vulnerability of patients with HFpEF 
to preload reduction. 32 As venodilator eff ects were sug-
gested to play an important role in reducing LV fi lling 
pressures with nitroprusside, 32 the signifi cant increase in 
SV with riociguat could potentially be explained by a 
diff erent regional vasoactivity, which may increase 
cGMP in the heart and arteries with less of the tolerability-
limiting preload reduction of NO donors. Despite 30% of 
patients experiencing a decrease in invasively measured 
systemic systolic arterial BP  , 80 mm Hg or invasively 
measured systemic mean arterial BP  , 60 mm Hg 
following single doses of riociguat 2 mg, many patients 
did not have signifi cant signs and symptoms of hypoten-
sion. Nevertheless, as the extent of systemic BP reduc-
tion with ad hoc dosing of riociguat 2 mg may be more 
appropriate in patients with higher baseline BP, riociguat 
should, like angiotensin-converting enzyme inhibitors, 
be started at low doses and up-titrated in future longer-
term studies. Dosing should be handled similar to the 
LEPHT in patients with HF and reduced ejection 
fraction. 21 
 In single-center clinical studies in HFpEF, sildenafi l 
improved pulmonary artery pressure and right-sided 
heart function . 33 However, sildenafi l failed to improve 
peak O 2 consumption in the Phosphodiesterase-5 Inhi-
bition to Improve Clinical Status and Exercise Capacity 
in Diastolic Heart Failure (RELAX) study and showed 
no signifi cant benefi t vs placebo in a range of secondary 
end points in patients with HFpEF. 34 Moreover, subgroup 
analysis showed no improvement in peak O 2 consump-
tion in patients with higher pulmonary artery systolic 
pressure (median pulmonary artery systolic pressure was 
41 mm Hg [range, 32-51 mm Hg] in the treatment group). 
In contrast to the signifi cant reduction of SVR observed 
in the present study, and with chronic riociguat therapy 
in the LEPHT, 21 SVR was unchanged aft er 6 months of 
treatment with sildenafi l. 34 Th e RELAX investigators 
speculated that the ability of phosphodiesterase-5 inhib-
itors to enhance cGMP might be limited by insuffi  cient 
 TABLE 4 ]  Incidence of Adverse Events (Safety Population) 
Adverse Event Placebo (n  5 13)
Riociguat
0.5 mg (n  5 8) 1 mg (n  5 8) 2 mg (n  5 10)
Any adverse event 4 (31) 3 (38) 3 (38) 5 (50)
Atrial ﬂ utter 0 0 0 1 (10)
Fall 0 0 1 (13) 0
Traumatic hematoma 1 (8) 0 0 0
Serum potassium decreased 0 1 (13) 0 0
Cardiac output decreased 2 (15) 0 0 1 (10)
Mean arterial pressure decreased 1 (8) 0 1 (13) 3 (30)
Muscle hemorrhage 0 0 1 (13) 0
Musculoskeletal pain 1 (8) 0 0 0
Dizziness 1 (8) 0 0 0
Acute renal failure 0 0 0 1 (10)
Dyspnea 0 1 (13) 0 0
Hemothorax a 0 0 1 (13) 0
Pulmonary hemorrhage 0 0 1 (13) 0
Pulmonary edema 0 1 (13) 0 0
Drug eruption b 0 0 1 (13) 0
Skin neoplasm excision 0 1 (13) 0 0
 Data are presented as No. (%). 
 a The events hemothorax and pulmonary hemorrhage occurred in one patient and relate to the insertion of the right-sided heart catheter. The 
procedure was required by study protocol. Both events were consequently assessed as unrelated to riociguat. 
 b Investigator term “exanthema because of Urosin allergy.” 
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endogenous stimulation of sGC secondary to reduced 
NO bioavailability in HFpEF. Th e results of the present 
study are, therefore, promising regarding the effi  cacy of 
direct, NO-independent sGC stimulation in patients 
with HFpEF. 35 
 Th e main limitation of this single-dose study was the 
relatively small number of patients in each treatment 
group, which prevented analysis of subgroups of partic-
ular interest (eg, high vs low TPG, AF vs sinus rhythm). 
Th e number of patients with diastolic pressure gradient 
(DPG)   7 mm Hg was fi ve of 36, thus precluding a valid 
statistical evaluation of this subgroup. Assessment of 
riociguat in patients with combined precapillary and post-
capillary PH (PAWP  . 15 mm Hg, DPG   7 mm Hg), as 
opposed to isolated postcapillary PH (PAWP  . 15 mm Hg, 
DPG  , 7 mm Hg), 36 could be considered for future 
studies to explore treatment benefi ts in this population. 
 Baseline diff erences between groups included higher 
rates of AF at baseline in the riociguat 2 mg group com-
pared with placebo and higher LV end-diastolic volume, 
SV, LA area, and right ventricular area in riociguat 
groups than in placebo. Th us, an infl uence of the extent 
of remodeling and structural changes on the observed 
results cannot be excluded. 
 Th e presence of patients with AF in the DILATE study 
may have aff ected the accuracy of hemodynamic mea-
surements. However, this limitation was minimized by 
the study protocol recommending that investigators use 
an average of fi ve measurements during thermodilution 
in patients with AF vs three for those in sinus rhythm. 
 Hemodynamic tracings and echocardiography were 
conducted and read on site in accordance with the stan-
dards at each institution; only key echocardiographic 
parameters were measured to allow for adherence to 
the protocol-defi ned acquisition intervals (as short as 
30 min), without processing of results for central assess-
ment by core laboratories. Th e observed changes in fl ow 
were only assessed by a single method. Th ere was no 
signifi cant change in mixed venous oxygen saturation, 
suggesting that the actual change in CO with riociguat 
was lower than that observed using thermodilution, 
although direct assessment of oxygen consumption 
was not performed. Furthermore, there were no study-
specifi c standardization procedures regarding end-
expiratory capture and analysis of PAWP at mid-A; 
local standards defi ned their acquisition. 
 Finally, the hemodynamic and echocardiographic 
eff ects of single doses of riociguat in this exploratory 
phase 2b study cannot be extrapolated to short-term 
(weeks) or long-term (months to years) treatment 
responses. Chronic, large-scale, placebo-controlled 
studies are required, which should include blinded cen-
tral reading of hemodynamic and echocardiographic 
measurements. 
 Conclusions 
 In conclusion, single doses of riociguat were well toler-
ated and showed favorable hemodynamic and echocar-
diographic eff ects in patients with HFpEF and PH. 
Riociguat 2 mg signifi cantly increased SV and cardiac 
index, and decreased systolic BP, SVR, and RVED area, 
without altering HR, TPG, or PVR. Th e ventricular 
fi lling required to establish an increased SV was not 
accompanied by increased PAWP, raising the hypothesis 
that in addition to its systemic vasodilatory eff ect, rio-
ciguat could improve diastolic function. Future clinical 
studies should include the titration of oral sGC stimula-
tors over a longer period of time in patients with HFpEF. 
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